The Europe Acne Drugs Market size is expected to grow at a prominent CAGR from 2021 to 2026.
Growing pollution levels in the European countries increase the incidence of skin dryness among the public and their unhealthy lifestyles to majorly boost the growth of the acne drugs market in Europe. Increasing population and surging demand for the utilization of acne products in the market are accelerating the growth. FDA approvals towards the skincare products and Y-O-Y growth in the hormonal imbalance are anticipated to stimulate the market's acne medication treatment. About 80% of the people aged between 11 to 30 years will expose to acne. Funds and investments available for the research and developments of acne products, enormous patient population, and the growing teenage population are likely to stimulate market growth. Around 507 million residents are there in the European region, according to Eurostat in 2014, and amid the population, 79 million are children growing up to 14 years of age.
The availability of substitute acne treatment options such as laser therapies may restrain the market growth to a limited extent. Side-affects arise with acne medication like topical acne drugs causing skin dryness and oral medication, increasing the risk of blood clots, and high blood pressure are restraining the market growth during the analysis period. The high cost of treatment procedures like microdermabrasion and dermabrasions is a barrier to market growth in the region.
This research report on the European acne drugs market has been segmented & sub-segmented into the following categories:
By Type:
By Route of Administration:
By Drug Class:
By Country:
Regional Analysis:
The European acne drugs market is expected to hold the second-largest share in the global market during the forecast period. Factors such as growing significant acne problems specifically in young adults like teenagers, particularly in women, and rising consciousness in consumers regarding acne treatment and medication, boost the market growth in this region. The utilization of acne medication in the area owes due to an increase in marketing programs organized by important key players of the region drives the market further. Germany is dominating the acne medication market, followed by the UK. In Germany, the market share is caused by factors like growth in consumers' discretionary expenses in purchasing acne products and increasing people's issues about their physical appearance. The UK owes to factors like advancements in technology, escalating necessity for cosmetics, and lifestyle changes.
Some of the major companies dominating the European acne drugs market by their products and services include Pfizer, Inc., GlaxoSmithKline plc, Novartis AG, Merck & Co. Inc., Amgen, Inc., Abbott Laboratories, AstraZeneca, Eli Lilly and Company, Mylan N.V., and Daiichi Sankyo Company, Ltd.
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Type
5.1.1 Introduction
5.1.2 OTC drugs
5.1.3 Prescription drugs
5.1.4 Y-o-Y Growth Analysis, By type
5.1.5 Market Attractiveness Analysis, By type
5.1.6 Market Share Analysis, By type
5.2 Route of administration
5.2.1 Introduction
5.2.2 Topical
5.2.3 Oral
5.2.4 Y-o-Y Growth Analysis, By route of administration
5.2.5 Market Attractiveness Analysis, By route of administration
5.2.6 Market Share Analysis, By route of administration
5.3 Drug class
5.3.1 Introduction
5.3.2 Antibiotics
5.3.3 Anti-inflammatory drugs
5.3.4 Anti-microbials
5.3.5 Combination drugs
5.3.6 Hormonal agents
5.3.7 Oral retinoids
5.3.8 Topical retinoids
5.3.7 Y-o-Y Growth Analysis, By drug class
5.3.8 Market Attractiveness Analysis, By drug class
5.3.9 Market Share Analysis, By drug class
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By type
6.1.3.3 By route of administration
6.1.3.4 By drug class
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By type
6.1.4.3 By route of administration
6.1.4.4 By drug class
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By type
6.1.5.3 By route of administration
6.1.5.4 By drug class
6.2 U.K
6.3 Spain
6.4 Germany
6.5 Italy
6.6 France
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Pfizer Inc.
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 GlaxoSmithKline plc
8.3 Novartis AG
8.4 Merck & Co. Inc
8.5 Amgen, Inc.
8.6 Abbott Laboratories
8.7 Eli Lilly and Company
8.8 Daiichi Sankyo Company, Ltd
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
Apr 2021
